NYSE · CIK 0001006281
PLX Protalix BioTherapeutics, Inc.
Insider trading from SEC Form 4. Last filing 33 d ago. Close $2.78 on Oct 9, 2026, +66% from the 52-week low and -12% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Price and insider trades, last year
PLXOct 9, 2026 · close 2.78
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Protalix BioTherapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 41Moderate | Dror Bashan PRESIDENT AND CEO buy | $101k 56,000 shares | +42% | - | |
| 35Weak | Amos Bar-Shalev director sell | $314 168 shares | -100% | - | |
| 37Weak | Aharon Schwartz director buy | $206k 129,000 shares | +74% | - |
Transactions
The last 40 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | Aharon Schwartz director | AGrant or award Stock Options (Right to Buy)derivative | +17,000 | $0.00 | $0 | 17,000 | 33 d ago |
| Sep 3, 2026 | Aharon Schwartz director | AGrant or award Restricted Stock Unitsderivative | +8,500 | $0.00 | $0 | 8,500 | 33 d ago |
| Sep 3, 2026 | Amos Bar-Shalev director | AGrant or award Stock Options (Right to Buy)derivative | +17,000 | $0.00 | $0 | 17,000 | 38 d ago |
| Sep 3, 2026 | Dror Bashan PRESIDENT AND CEO | AGrant or award Stock Option (Right to Buy)derivative | +320,000 | $0.00 | $0 | 320,000 | 38 d ago |
| Sep 3, 2026 | Zvi Shmuel Ben director | AGrant or award Stock Options (Right to Buy)derivative | +17,000 | $0.00 | $0 | 17,000 | 38 d ago |
| Sep 3, 2026 | Pol F Boudes director | AGrant or award Stock Options (Right to Buy)derivative | +17,000 | $0.00 | $0 | 17,000 | 38 d ago |
| Sep 3, 2026 | Christian Elze director | AGrant or award Stock Options (Right to Buy)derivative | +17,000 | $0.00 | $0 | 17,000 | 38 d ago |
| Sep 3, 2026 | Yaron Naos Sr. VP & COO | AGrant or award Stock Option (Right to Buy)derivative | +112,000 | $0.00 | $0 | 112,000 | 38 d ago |
| Sep 3, 2026 | Eliot Forster director | AGrant or award Stock Options (Right to Buy)derivative | +17,000 | $0.00 | $0 | 17,000 | 38 d ago |
| Sep 3, 2026 | Gwen A Melincoff director | AGrant or award Stock Options (Right to Buy)derivative | +17,000 | $0.00 | $0 | 17,000 | 38 d ago |
| Sep 3, 2026 | Amos Bar-Shalev director | AGrant or award Restricted Stock Unitsderivative | +8,500 | $0.00 | $0 | 8,500 | 38 d ago |
| Sep 3, 2026 | Yaron Naos Sr. VP & COO | AGrant or award Restricted Stock Unitsderivative | +56,000 | $0.00 | $0 | 56,000 | 38 d ago |
| Sep 3, 2026 | Gwen A Melincoff director | AGrant or award Restricted Stock Unitsderivative | +8,500 | $0.00 | $0 | 8,500 | 38 d ago |
| Sep 3, 2026 | Eliot Forster director | AGrant or award Restricted Stock Unitsderivative | +8,500 | $0.00 | $0 | 8,500 | 38 d ago |
| Sep 3, 2026 | Christian Elze director | AGrant or award Restricted Stock Unitsderivative | +8,500 | $0.00 | $0 | 8,500 | 38 d ago |
| Sep 3, 2026 | Pol F Boudes director | AGrant or award Restricted Stock Unitsderivative | +8,500 | $0.00 | $0 | 8,500 | 38 d ago |
| Sep 3, 2026 | Zvi Shmuel Ben director | AGrant or award Restricted Stock Unitsderivative | +8,500 | $0.00 | $0 | 8,500 | 38 d ago |
| Sep 3, 2026 | Dror Bashan PRESIDENT AND CEO | AGrant or award Restricted Stock Unitsderivative | +160,000 | $0.00 | $0 | 160,000 | 38 d ago |
| Dec 19, 2025 | Dror Bashan PRESIDENT AND CEO | POpen-market purchase Common Stock | +56,000 | $1.81 | $101k | 188,516 | Dec 23, 2025 |
| Nov 18, 2025 | Amos Bar-Shalev director | SOpen-market sale Common Stock | -168 | $1.87 | $314 | 0 | Nov 19, 2025 |
| Sep 3, 2025 | Amos Bar-Shalev director | AGrant or award Common Stockindirect: By Trust | +7,500 | - | - | 7,500 | Sep 4, 2025 |
| Sep 3, 2025 | Aharon Schwartz director | AGrant or award Common Stockindirect: By Trust | +7,500 | - | - | 7,500 | Sep 4, 2025 |
| Sep 3, 2025 | Yaron Naos Sr. VP, Operations | AGrant or award Common Stockindirect: By Trust | +25,000 | - | - | 225,817 | Sep 4, 2025 |
| Sep 3, 2025 | Gwen A Melincoff director | AGrant or award Common Stockindirect: By Trust | +7,500 | - | - | 7,500 | Sep 4, 2025 |
| Sep 3, 2025 | Eliot Forster director | AGrant or award Common Stockindirect: By Trust | +7,500 | - | - | 7,500 | Sep 4, 2025 |
| Sep 3, 2025 | Christian Elze director | AGrant or award Common Stockindirect: By Trust | +7,500 | - | - | 7,500 | Sep 4, 2025 |
| Sep 3, 2025 | Pol F Boudes director | AGrant or award Common Stockindirect: By Trust | +7,500 | - | - | 7,500 | Sep 4, 2025 |
| Sep 3, 2025 | Zvi Shmuel Ben director | AGrant or award Common Stockindirect: By Trust | +7,500 | - | - | 7,500 | Sep 4, 2025 |
| Sep 3, 2025 | Dror Bashan PRESIDENT AND CEO | AGrant or award Common Stockindirect: By Trust | +195,000 | - | - | 2,344,418 | Sep 4, 2025 |
| Sep 3, 2025 | Zvi Shmuel Ben director | AGrant or award Stock Options (Right to Buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Sep 4, 2025 |
| Sep 3, 2025 | Christian Elze director | AGrant or award Stock Options (Right to Buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Sep 4, 2025 |
| Sep 3, 2025 | Eliot Forster director | AGrant or award Stock Options (Right to Buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Sep 4, 2025 |
| Sep 3, 2025 | Gwen A Melincoff director | AGrant or award Stock Options (Right to Buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Sep 4, 2025 |
| Sep 3, 2025 | Pol F Boudes director | AGrant or award Stock Options (Right to Buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Sep 4, 2025 |
| Sep 3, 2025 | Dror Bashan PRESIDENT AND CEO | AGrant or award Stock Option (Right to Buy)derivative | +340,000 | $0.00 | $0 | 340,000 | Sep 4, 2025 |
| Sep 3, 2025 | Yaron Naos Sr. VP, Operations | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Sep 4, 2025 |
| Sep 3, 2025 | Amos Bar-Shalev director | AGrant or award Stock Options (Right to Buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Sep 4, 2025 |
| Sep 3, 2025 | Aharon Schwartz director | AGrant or award Stock Options (Right to Buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Sep 4, 2025 |
| Jun 10, 2025 | Aharon Schwartz director | POpen-market purchase Common Stock | +129,000 | $1.60 | $206k | 303,000 | Aug 12, 2025 |
| Sep 23, 2024 | Eyal Rubin Sr. VP and CFO | AGrant or award Common Stockindirect: By Trust | +90,909 | - | - | 660,909 | Nov 5, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Amos Bar-Shalevdirector
- Dror BashanPRESIDENT AND CEO
- Zvi Shmuel Bendirector
- Pol F Boudesdirector
- Christian Elzedirector
- Eliot Forsterdirector
- Gwen A Melincoffdirector
- Yaron NaosSr. VP, Operations
- Eyal RubinSr. VP and CFO
- Aharon Schwartzdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.